High-Quality Felodipine for Antihypertensive: Factory Quotes Available

Introducing Felodipine, an effective antihypertensive medication offered by Shanghai Theorem Chemical Technology Co., Ltd. Felodipine belongs to the class of medications called calcium channel blockers, which work by relaxing the blood vessels, making it easier for the heart to pump blood and lowering blood pressure. This medication is commonly prescribed to manage high blood pressure and prevent chest pain (angina), Our company, Shanghai Theorem Chemical Technology Co., Ltd., is dedicated to providing high-quality pharmaceutical products, including Felodipine, to meet the needs of patients and healthcare professionals. Our commitment to excellence in manufacturing and stringent quality control processes ensures the safety and efficacy of our products, Felodipine is available in various dosage strengths to cater to individual patient needs. It is important to take Felodipine exactly as prescribed by a healthcare provider to achieve maximum benefits in managing hypertension. As a trusted supplier of pharmaceutical products, Shanghai Theorem Chemical Technology Co., Ltd. is proud to offer Felodipine as part of our comprehensive range of antihypertensive medications

Hot Selling Product

99% Dimethoxy dipropyleneglycol CAS 111109-77-4 dipropylene glycol dimethyl ether, mixture of isomers

2-Bromo-5-methoxytoluene cas 27060-75-9

1-Chlorohexane 99% CAS：544-10-5

N-hydrogenated tallow-1,3- propylene diamine (diamine 86) CAS 68603-64-5

Supply high quality 99% Fluorographene CAS 51311-17-2 Graphene fluoride powder with good price fluorinated Graphite (Carbon fluoride)

plasticizer ATBC Acetyl tributyl citrate CAS 77-90-7

Leading Chinese Felodipine for Antihypertensive Service Supplier

In the rapidly evolving pharmaceutical landscape, the demand for effective antihypertensive solutions continues to grow. Felodipine, a prominent dihydropyridine calcium channel blocker, has proven to be a reliable medication for managing hypertension. With a focus on quality and innovation, we stand out as a leading supplier specializing in the research and production of this vital compound. Our commitment to developing functional materials and fine chemicals ensures that our Felodipine not only meets but exceeds industry standards, providing clients with a product they can trust. Our expertise in advanced chemical processes, including the production of surfactants and various isocyanates, positions us uniquely to meet the specific needs of global procurement agents. By harnessing state-of-the-art technology and rigorous quality control measures, we aim to deliver high-purity Felodipine that supports healthcare providers in delivering effective treatment options. As the market expands, our dedication to sustainability and innovation guarantees that we can adapt to the evolving demands of the pharmaceutical sector. Choosing us as your Felodipine supplier means partnering with a company that values integrity, quality, and customer satisfaction. We understand the challenges faced by global buyers and are committed to providing reliable support and superior products that enhance healthcare outcomes. Together, let us make a significant impact on the fight against hypertension worldwide.

Leading Chinese Felodipine for Antihypertensive Service Supplier

Product Name	Active Ingredient	Dosage Forms	Strength	Market Approval Date	Manufacturer Location
Felodipine Tablets	Felodipine	Tablets	2.5 mg, 5 mg, 10 mg	2010-05-15	Beijing, China
Felodipine Extended-Release Capsules	Felodipine	Capsules	5 mg, 10 mg	2015-11-21	Shanghai, China
Felodipine Oral Suspension	Felodipine	Oral Suspension	1 mg/ml	2018-08-30	Guangzhou, China

Trends in Antihypertensive Drug Utilization in China

The above chart illustrates the trends in the utilization of felodipine compared to other antihypertensive drugs in China from 2019 to 2023. In recent years, felodipine has shown a significant increase in usage, reflecting a growing preference among healthcare providers for this particular medication due to its efficacy and safety profile. Starting from a utilization rate of 15 million units in 2019, felodipine usage surged to 35 million units by 2023. This indicates a growing acceptance and reliance on felodipine as a first-line treatment option for managing hypertension. Conversely, the utilization of other antihypertensive medications has shown a decline from 50 million units in 2019 to 30 million units in 2023. This trend may suggest a shift in prescribing habits, possibly influenced by new clinical guidelines, emerging research, and patient outcomes associated with felodipine. As hypertension remains a significant public health challenge, the increasing utilization of felodipine may provide insights into effective management strategies within the healthcare system. The data underscores the importance of continual research and adaptation in pharmaceutical practices to optimize patient care.